What Is Peptide Therapy? A Physician's Complete Guide

At a Glance

If you are researching peptide therapy for the first time, you are likely encountering a confusing landscape. Social media influencers promote peptides as if they are supplements you can casually add to your routine. Some physicians dismiss them entirely. The truth, as usual, is more nuanced than either extreme.

I prescribe peptides daily in my clinical practice at Klinik St. Georg in Germany. Some of them have transformed patient outcomes. Others have disappointed. And the honest reality is that many sit in a gray zone where the preclinical evidence is strong, the clinical observation is encouraging, but the rigorous human trial data that would give us full confidence simply does not exist yet.

Here is what you need to know.

What Peptides Actually Are

A peptide is a short chain of amino acids linked by peptide bonds. The distinction between a peptide and a protein is primarily one of size: peptides typically contain 2 to 50 amino acids, while proteins are longer chains (often hundreds to thousands of amino acids) with complex three-dimensional structures.

Your body produces thousands of peptides naturally. They function as signaling molecules — hormones, neurotransmitters, growth factors, antimicrobial agents. Insulin, for example, is a peptide hormone. So is oxytocin. So is glucagon-like peptide-1 (GLP-1), the target of semaglutide.

Peptide therapy means administering specific peptides — either naturally occurring or synthetically engineered — to produce targeted biological effects.

Why Peptides Are Different from Drugs

Traditional pharmaceutical drugs are typically small molecules designed to block or activate a receptor broadly. Peptides are more specific. Because they mimic natural signaling molecules, they tend to interact with defined receptor targets and produce more targeted effects with, in many cases, fewer off-target side effects.

This specificity is both their advantage and their limitation. A peptide that targets tissue repair through VEGF upregulation does exactly that — it does not also lower blood pressure, change mood, or affect liver metabolism the way many small-molecule drugs do. But this specificity also means that complex conditions often require multiple peptides addressing different pathways.

The Size Matters

Peptides are larger than conventional drugs but smaller than biologics (monoclonal antibodies, for instance). This intermediate size creates practical challenges:

• Oral bioavailability is generally poor. Most peptides are broken down by digestive enzymes before they reach the bloodstream. This is why most peptide therapies are administered by injection. (Some peptides, like BPC-157, show unusual stability in gastric acid and retain oral activity.)
• Shelf life requires attention. Peptides can degrade with heat, light, and improper storage. Reconstituted peptides typically need refrigeration.
• Synthesis quality varies. Manufacturing peptides to pharmaceutical-grade purity is technically demanding. The unregulated market has documented quality issues.

How Peptide Therapy Works

The Receptor Model

Peptides work by binding to specific receptors on or inside cells, triggering a cascade of biological responses. Think of it as a key-and-lock system: the peptide is the key, the receptor is the lock, and the biological response is what happens when the door opens.

Different peptides activate different receptors, which is why peptide therapy is not a single treatment but a category of treatments — each peptide has its own mechanism, evidence base, and clinical application.

Categories of Therapeutic Peptides

In my clinical practice, I work with peptides across several functional categories:

Tissue repair peptides. BPC-157 and TB-500 promote tissue healing through complementary mechanisms — angiogenesis and cellular migration, respectively. Used for gut healing, tendon repair, muscle recovery, and post-surgical support.

Growth hormone secretagogues. CJC-1295 and Ipamorelin stimulate the pituitary gland to release more growth hormone through natural pathways. Used for body composition, recovery, sleep quality, and anti-aging protocols. These are not exogenous growth hormone — they stimulate your own production.

Immune-modulating peptides. Thymosin alpha-1 supports immune function through T-cell activation and dendritic cell maturation. Used in chronic infections, immune deficiency, and as adjunctive cancer support. Thymosin alpha-1 is actually approved as a prescription medication (Zadaxin) in several countries.

Neuroprotective peptides. Selank, Semax, and Dihexa target neurological function — cognitive enhancement, neuroprotection, and neuroregeneration. Evidence levels vary substantially within this category.

Anti-aging peptides. Epithalon targets telomerase activation. GHK-Cu promotes collagen synthesis and skin remodeling. These operate on mechanisms implicated in aging but with varying degrees of clinical validation.

Antimicrobial peptides. LL-37 and other naturally occurring antimicrobial peptides are being investigated for their role in infection management, biofilm disruption, and immune defense.

The Evidence Landscape: An Honest Assessment

This is where I must be direct, because the peptide space is plagued by both overclaiming and underclaiming.

FDA-Approved Peptides: Strong Evidence

Several peptides are fully approved medications with robust clinical trial data:

These peptides went through the full regulatory process: Phase I through Phase III clinical trials, safety monitoring, and post-marketing surveillance. When I prescribe these, I am working with conventional pharmaceutical evidence.

Investigational Peptides: Emerging Evidence

The majority of peptides used in integrative and regenerative medicine are investigational. Their evidence base typically includes:

• Extensive preclinical (animal) studies — often dozens to hundreds of published papers
• Mechanistic studies demonstrating how they work at the molecular level
• Limited small-scale human studies or case series
• Clinical observation from physicians who prescribe them
• Patient-reported outcomes from the broader peptide community

Here is what I tell my patients: the absence of large human trials does not mean these peptides do not work. It means the evidence is incomplete. Many of them produce consistent clinical results in my practice. But “I observe it works” and “it has been proven in controlled human trials” are different statements, and I do not conflate them.

What to Expect: A Typical Peptide Therapy Journey

Initial Consultation

A responsible peptide therapy program begins with a thorough evaluation. In my practice, this includes:

• Comprehensive health history and medication review
• Relevant laboratory work (hormone panels, inflammatory markers, organ function)
• Discussion of goals, expectations, and timeline
• Risk-benefit assessment specific to the patient’s conditions and contraindications
• Selection of the appropriate peptide(s) and route of administration

Peptide therapy is not one-size-fits-all. A 35-year-old athlete with a tendon injury needs a different approach than a 55-year-old executive seeking cognitive optimization or a chronic Lyme patient pursuing multi-system recovery.

Administration

Subcutaneous injection is the most common route. This involves a small insulin-type needle injected into the fatty tissue of the abdomen, thigh, or upper arm. Most patients learn the technique in one session and self-administer at home. It is significantly less intimidating than it sounds.

Oral administration is available for some peptides. BPC-157 shows unusual gastric acid stability and retains some efficacy orally, particularly for GI targets. Most other peptides are degraded by digestive enzymes.

Nasal administration is used for some neuropeptides (Selank, Semax) to bypass the blood-brain barrier.

Intravenous infusion is used for NAD+ and some immune-modulating protocols. This requires a clinical setting.

Timeline

Peptide therapy is not instantaneous. Typical timelines in my clinical experience:

Monitoring

Responsible peptide therapy requires follow-up. At minimum:

• Symptom tracking (subjective response)
• Relevant laboratory monitoring (IGF-1 for GH secretagogues, inflammatory markers for immune peptides)
• Side effect assessment
• Protocol adjustment based on response

Cost Considerations

Peptide therapy costs vary widely based on the specific peptide, dosing, source, and clinical setting.

A typical 8-week BPC-157 cycle for a tendon injury might cost 300 to 600 EUR total including the peptide, supplies, and one follow-up consultation. A comprehensive longevity protocol with multiple peptides could run 500 to 1,500 EUR per month.

Insurance coverage varies by country and provider. In most jurisdictions, investigational peptides are not covered by insurance. FDA-approved peptides (semaglutide, sermorelin) may be covered when prescribed for approved indications.

Risks and Limitations

General Risks

• Limited human safety data for most investigational peptides
• Product quality variation in the unregulated market — contamination, mislabeling, and degradation are documented
• Injection-related risks — infection (rare with proper technique), bruising, discomfort
• Unknown long-term effects — most peptides have been used clinically for years, not decades

Who Should Not Use Peptide Therapy

• Patients with active malignancy (many peptides promote growth factor signaling or angiogenesis)
• Pregnant or lactating women (no safety data)
• Children and adolescents (except for FDA-approved indications with pediatric data)
• Patients with hypersensitivity to specific peptides
• Patients who cannot commit to proper medical supervision and monitoring

The Sourcing Problem

This deserves emphasis because it is a genuine patient safety issue. The peptide market includes both pharmaceutical-grade products from regulated manufacturers and gray-market products of uncertain quality. Independent analyses have found products with incorrect concentrations, bacterial contamination, heavy metals, and in some cases entirely different compounds than labeled.

If you pursue peptide therapy, pharmaceutical-grade sourcing with third-party certificate of analysis is non-negotiable. This is not an area where cost savings are worth the risk.

How to Find a Qualified Prescriber

Not every physician is equipped to prescribe peptide therapy. Look for:

• Medical degree and active license — this should be obvious, but the peptide space attracts non-medical practitioners
• Training in integrative, regenerative, or anti-aging medicine — organizations like A4M (American Academy of Anti-Aging Medicine) or AMMG provide peptide-specific training
• Clinical experience with the specific peptides they are recommending
• Willingness to discuss evidence levels honestly — a physician who presents investigational peptides as proven treatments is not being transparent
• Proper monitoring protocols — laboratory follow-up, side effect tracking, and protocol adjustment

A physician who prescribes a peptide and disappears until refill time is not practicing responsible medicine.

What I Tell My Patients

Peptide therapy is a legitimate therapeutic approach with real applications, real limitations, and real unknowns. It sits at the intersection of established pharmacology (FDA-approved peptides like insulin and semaglutide) and investigational medicine (BPC-157, TB-500, and the growing repertoire of therapeutic peptides).

The responsible approach is:

1. Start with a clear therapeutic goal — not “I want peptides” but “I want to heal this tendon” or “I want to optimize my growth hormone levels”
2. Work with a qualified physician who understands the evidence hierarchy
3. Use pharmaceutical-grade products from verified sources
4. Monitor your response with appropriate laboratory and clinical follow-up
5. Maintain realistic expectations about what the current evidence supports

Peptide therapy is not magic. It is pharmacology — targeted, specific, and often effective, but bounded by the same rules of evidence that govern all of medicine.

References

1. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. 2015;20(1):122-128. doi:10.1016/j.drudis.2014.10.003.
2. Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorganic & Medicinal Chemistry. 2018;26(10):2700-2707. doi:10.1016/j.bmc.2017.06.052.
3. Muttenthaler M, et al. Trends in peptide drug discovery. Nature Reviews Drug Discovery. 2021;20(4):309-325. doi:10.1038/s41573-020-00135-8.
4. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612-1632. PMID: 21548867.
5. Goldstein AL, et al. Thymosin beta-4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy. 2012;12(Suppl 1):S37-S51. doi:10.1517/14712598.2012.666616.
6. Garza-Mayers AC, et al. The evolving landscape of peptide therapeutics. Annual Review of Pharmacology and Toxicology. 2023;63:279-303.
7. Wang L, et al. Therapeutic peptides: current applications and future challenges. Signal Transduction and Targeted Therapy. 2022;7(1):48. doi:10.1038/s41392-022-00904-4.

This content is educational and does not constitute medical advice. Investigational peptides should only be used under the supervision of a qualified physician. Consult your healthcare provider before starting any peptide therapy program.